Phaseline

Companies › Alveus Therapeutics

Alveus Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALV-100–Phase 2Overweight , Obesity; Overweight or Obese AdultsAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07837973ALV-100Phase 2Overweight , ObesityMetabolic and endocrineAug 2027
NCT07399678ALV-100Phase 1Overweight or Obese AdultsMetabolic and endocrineOct 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Amorphical ERX Pharmaceuticals Hyundai Pharm Rare Thyroid Therapeutics International River 3 Renal

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.